Financial Performance - The company's operating revenue for 2024 reached ¥6,031,865,460.16, representing a 16.44% increase compared to ¥5,180,441,799.76 in 2023[22]. - The net profit attributable to shareholders for 2024 was ¥1,549,164,832.24, a 39.58% increase from ¥1,109,888,597.22 in the previous year[22]. - Basic earnings per share for 2024 were ¥0.78, up 39.58% from ¥0.56 in 2023[24]. - The weighted average return on equity increased to 14.81%, up 2.88 percentage points from 11.93% in 2023[24]. - The company achieved an annual revenue of 603.19 million RMB, representing a year-on-year growth of 16.44%[34]. - The net profit for the year was 211.23 million RMB, with a year-on-year increase of 39.94%[34]. - The net profit attributable to shareholders was 154.92 million RMB, reflecting a growth of 39.58% compared to the previous year[34]. - The gross profit margin for the biopharmaceutical industry was 54.67%, up by 3.94 percentage points year-on-year[89]. - The company reported a net profit attributable to ordinary shareholders of 1,549,164,832.24 RMB for the most recent fiscal year[187]. - The cash dividend amount represents 12.76% of the net profit attributable to ordinary shareholders[184]. Assets and Cash Flow - The total assets of the company at the end of 2024 were ¥15,869,522,217.56, an 11.85% increase from ¥14,188,056,936.91 in 2023[23]. - The net cash flow from operating activities decreased by 65.75% to ¥819,780,705.09, down from ¥2,393,576,031.26 in 2023[22]. - Cash and cash equivalents decreased by 41.04% to ¥2,685,655,918.86 due to changes in credit policy and increased expenditures from the acquisition of Zhongyuan Ruide[100]. - Accounts receivable increased by 1,036.25% to ¥203,000,923.47, attributed to changes in sales credit policy[100]. - Inventory increased by 36.02% to ¥3,869,072,356.24, driven by the acquisition of Zhongyuan Ruide and increased production volume[100]. - The net cash flow from investing activities was -185,911.62 million CNY, a decrease of 61,220.93 million CNY compared to the previous year[97]. Plasma Collection and Production - The company collected a total of 2,781 tons of plasma, marking a 15.15% increase year-on-year, maintaining a leading position in the domestic market[35]. - The company has 85 operational single plasma collection stations, which contributed to the increase in plasma collection[35]. - The company accelerated plasma production, achieving annual plasma collection targets and ensuring product supply according to market demand[37]. - The company operates 107 plasma collection stations across 16 provinces, with 85 stations actively collecting plasma, achieving a total collection of 2,781 tons, representing approximately 20% of the domestic market share[62]. - The company has a production capacity of 1,200 tons at each of its three new production bases in Chengdu, Kunming, and Lanzhou, which are expected to enhance operational quality and efficiency[64]. Research and Development - The company received 22 authorized patents during the reporting period, including 3 invention patents and 19 utility model patents, reflecting strong R&D progress[39]. - The company maintains a leading position in R&D with over 100 researchers and advanced facilities, focusing on the development of recombinant coagulation factors and immunoglobulin products, with more than ten products currently under research[63]. - The company emphasizes a strong commitment to R&D, maintaining high levels of investment and focusing on the development of blood products and recombinant products[108]. - Key R&D projects include recombinant coagulation factors, with several products in various stages of clinical trials, including phase III and phase I trials[109]. - The company has successfully obtained regulatory approvals for several new products, including human prothrombin complex and intravenous immunoglobulin, which will enhance its product portfolio[111]. Market Expansion and Sales - The company expanded its sales coverage to over 700 top-tier hospitals across more than 30 provincial administrative regions, focusing on pediatric, neurological, and critical care departments[40]. - The company has established a sales network covering nearly 30,000 hospitals, effectively reaching major provinces and cities in China[63]. - The company’s sales model includes government procurement bidding to determine pricing and distribution responsibilities through channel partners[71]. - The company’s procurement model for raw materials is based on a material requirements planning (MRP) system to ensure efficient production and inventory management[70]. - The company plans to enhance its strategic goals to become a leading blood products enterprise with international influence[79]. Corporate Governance and Management - The company has established a robust corporate governance structure, ensuring compliance with relevant laws and regulations, and maintaining independence from its controlling shareholder[149]. - The board of directors consists of 7 members, including 3 independent directors, meeting the legal requirement for independent oversight[151]. - The company has implemented a performance evaluation system for senior management, linking compensation to company performance to enhance operational efficiency[152]. - The company actively respects the rights of stakeholders, including creditors and employees, fostering collaboration for sustainable development[152]. - The company has established specialized committees under the board, including Audit and Risk Management, Nomination, Performance Assessment and Compensation, and Strategic Investment Committees[169]. Environmental Compliance - The company is committed to environmental protection, ensuring compliance with national and industry standards for waste management[194]. - The hazardous waste management practices across all facilities have been confirmed to align with national hazardous waste regulations[197]. - Wastewater discharge from Chengdu Rongsheng showed no exceedance of the regulatory limits for COD, ammonia nitrogen, and BOD[194]. - The air pollution control facilities at Chengdu Rongsheng achieved compliance, with emissions from the heating boiler and VOCs treatment meeting standards[199]. - Chengdu Rongsheng processed a total of 386,756 m³ of wastewater during the reporting period, averaging 1,171.99 m³/d, with all effluent meeting national standards[199].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [4]. Core Views - The government has increased support for innovative drugs, which is expected to promote healthy development across various segments of the pharmaceutical industry [6][32]. - The report emphasizes a positive outlook for the pharmaceutical sector, particularly in the context of recent government policies aimed at enhancing healthcare services and drug innovation [27][32]. Summary by Sections Weekly Market Review - The pharmaceutical and biotechnology index rose by 2.02%, outperforming the CSI 300 index by 0.64 percentage points, ranking 18th in industry performance [9]. - Year-to-date, the index has increased by 6.53%, again surpassing the CSI 300 by 6.3 percentage points, ranking 14th [9]. - Sub-sectors such as medical services and medical devices showed significant gains, with medical services up 3.7% and medical devices up 3.29% for the week [13]. Individual Stock Performance - In the A-share market, 321 out of 477 pharmaceutical stocks rose, with notable gainers including Hotgen Biotech (+38.63%) and Berry Genomics (+34.39%) [18]. - In the Hong Kong market, 78 out of 106 pharmaceutical stocks increased, with top performers being HeartFlow Medical-B (+31.87%) and Hengrui Medicine-B (+30.19%) [22]. Industry News and Policies - The government work report highlighted the need for a collaborative approach to healthcare, emphasizing the integration of medical services, insurance, and pharmaceuticals [27]. - Key policies include optimizing drug procurement, enhancing quality assessments, and increasing financial support for basic medical insurance [33]. Weekly Insights - The report reiterates a bullish stance on the pharmaceutical sector, particularly in light of government initiatives to support innovative drug development and improve healthcare financing [32][34]. - Specific recommendations include focusing on companies in various segments such as raw materials, chemical preparations, and medical services, with suggested stocks like Hengrui Medicine and WuXi AppTec [34].

Group 1 - The overall profitability of the A-share market is weak, with cumulative net profit for non-financial companies down by 3.7% year-on-year, while operating revenue increased by 3.8% [6][15][12] - As of March 8, 2024, 1,066 listed companies have disclosed their performance reports, with 47% having previously issued earnings forecasts [6][12] - The performance of the CSI 500 index is superior, with a net profit growth of 8.7%, outperforming small-cap indices [15][16] Group 2 - The pharmaceutical and non-bank financial sectors are leading, with continuous acceleration in year-on-year growth [23][24] - In the upstream raw materials sector, oil, petrochemicals, and coal show strong performance, while non-ferrous metals experienced a slight decline in Q3 2024 but showed signs of recovery in Q4 2024 [23][24] - The TMT sector, particularly the electronics industry, continues to thrive due to AI-driven demand, with revenue and performance showing positive growth for four consecutive quarters [27][28] Group 3 - The banking and non-bank financial sectors have a high proportion of companies with both revenue and performance growth, indicating a favorable economic environment [36][39] - In the midstream manufacturing sector, all five industries reported negative net profit growth, with only basic chemicals and defense industries showing slight recovery [28][29] - The consumer goods sector, particularly pharmaceuticals and food and beverage, has shown significant growth, while textiles and retail remain weak [28][29] Group 4 - The expected net profit growth for the entire A-share market in 2025 is projected to be around 1.5%, with non-financial companies expected to see a 5% increase [23][24] - The performance of the component and aerospace equipment industries remains high, with significant improvements noted in the battery and military electronics sectors [42][46] - The overall performance of the main board and growth enterprise board is significantly better than that of the sci-tech innovation board and the northern stock exchange [15][16]

Investment Rating - The report does not explicitly state an investment rating for the industry [5] Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.06%, underperforming compared to the Wind All A index (2.43%) and the CSI 300 index (1.39%). The AI + healthcare sector experienced a significant rebound [10][11] - Key sectors that performed well include in vitro diagnostics (4.45%), active pharmaceutical ingredients (2.08%), and hospitals (1.85%). Conversely, offline pharmacies (-0.59%) and medical devices (-0.08%) saw declines [10][11] - The government work report emphasized strengthening basic medical and health services, implementing a health-first development strategy, and promoting the coordinated development of healthcare, medical insurance, and pharmaceuticals [12][14] - On March 8, Huawei announced the establishment of a healthcare division, aiming to integrate its expertise in 5G, cloud computing, and edge computing to develop AI-assisted diagnostic solutions [12][14] Weekly Market Review - The pharmaceutical and biotechnology sector increased by 1.06%, lagging behind the Wind All A index (2.43%) and the CSI 300 index (1.39%). The AI + healthcare direction showed a notable rebound [10] - The top-performing sub-sectors included in vitro diagnostics (4.45%), active pharmaceutical ingredients (2.08%), and hospitals (1.85%), while offline pharmacies (-0.59%) and medical devices (-0.08%) were the worst performers [10][11] - The top three gaining stocks were Hotgen Biotech (38.63%), Berry Genomics (34.39%), and Anbiping (25.72%), while the top three losing stocks were Jiangsu Wuzhong (-14.34%), ST Sansheng (-9.83%), and Baile Tianheng-U (-9.44%) [12][14] Industry News and Key Company Announcements - The government work report highlighted the need to enhance basic medical services and improve the healthcare system, including reforms in public hospitals and drug procurement policies [12][14] - Huawei's new healthcare division aims to leverage its technological strengths to accelerate the development of medical AI models for clinical applications [12][14] - On March 8, Ausgen announced that the FDA accepted its new drug application for AUKONTALS, a treatment for amyotrophic lateral sclerosis, with a decision expected by October 23, 2025 [12][14] - CloudTop announced the successful administration of its mRNA personalized cancer vaccine EVM16 in a clinical trial, marking a significant milestone in its development [12][14]

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [6]. Core Insights - Roche's innovative therapy TNKase has received FDA approval for the treatment of acute ischemic stroke (AIS), marking it as the first stroke medication approved in nearly 30 years [2][6]. - The pharmaceutical sector showed a performance increase of +0.54% on March 4, 2025, outperforming the CSI 300 index by 0.62 percentage points, ranking 19th among 31 sub-industries [1][6]. - Among sub-industries, in vitro diagnostics (+2.26%), medical devices (+1.17%), and hospitals (+0.85%) performed well, while other bioproducts (-0.06%), medical research outsourcing (+0.07%), and offline pharmacies (+0.17%) lagged [1]. Summary by Sections Market Performance - The pharmaceutical sector's performance on March 4, 2025, was +0.54%, outperforming the CSI 300 index by 0.62 percentage points, with in vitro diagnostics leading at +2.26% [1]. - Notable individual stock performances included BGI Genomics (+20.00%), Shengxiang Biology (+15.24%), and Aidi Pharmaceutical (+11.31%), while Jiangsu Wuzhong (-8.80%), Zhixiang Jintai (-6.22%), and Sihuan Bio (-6.01%) faced declines [1]. Company News - Yinos announced that its clinical immunohistochemistry laboratory received CAP certification, enhancing its clinical testing business prospects [2]. - Tiantan Biological reported that its human coagulation factor IX has completed clinical ethical review and is set to begin Phase III clinical trials, with cumulative R&D investment reaching 25.5766 million yuan [2]. - Sunshine Novo has repurchased 2.716789 million shares, accounting for 2.43% of its total share capital, with a total expenditure of approximately 99.75 million yuan [3]. - Tigermed has repurchased 9.8063 million shares, representing 1.1337% of its total share capital, with a total expenditure of approximately 500.12 million yuan [3].

证券研究报告 | 行业周报 2025 年 02 月 23 日 医药 本周医药板块上涨 1.88%，AI 医疗热度延续 | 股票 | 股票 | 投资 | EPS （元） | | PE | | | --- | --- | --- | --- | --- | --- | --- | | 代码 | 名称 | 评级 | 2024E | 2025E | 2024E | 2025E | | 002755.SZ | 奥赛康 | 买入 | 0.13 | 0.2 | 101.62 | 66.05 | | 01952.HK | 云顶新耀-B | 买入 | -2.93 | -0.12 | - | - | | 02105.HK | 来凯医药-B | 买入 | -0.9 | -1 | - | - | | 600079.SH | 人福医药 | 增持 | 1.33 | 1.59 | 15.02 | 12.56 | | 688192.SH | 迪哲医药 | 增持 | -2.01 | -1.33 | -22.96 | -34.7 | | 688315.SH | 诺禾致源 | 买入 | 0.47 | 0.53 | 41.0 | 36.36 | | ...

Financial Performance - Total operating revenue for 2024 reached CNY 603,352.86 million, an increase of 16.47% compared to the previous year[3] - Net profit attributable to shareholders increased by 39.42% year-on-year, amounting to CNY 154,743.19 million[3] - Basic earnings per share rose to CNY 0.78, reflecting a 39.42% increase from CNY 0.56 in the previous year[3] - The weighted average return on equity increased by 2.87 percentage points to 14.80%[3] Assets and Equity - Total assets at the end of the reporting period were CNY 1,584,794.47 million, up 11.70% from the beginning of the period[3] - The company's equity attributable to shareholders increased to CNY 1,113,697.14 million, a growth of 13.38%[3] - The net asset value per share decreased by 5.52% to CNY 5.63, adjusted for capital reserve conversion[3][4] Plasma Collection - The company collected 2,781 tons of plasma in 2024, a year-on-year increase of 15.15%[5] - The company operates 85 plasma collection centers, including subsidiaries, to enhance plasma collection capacity[5] Report Accuracy - The company emphasizes that there are no uncertainties affecting the accuracy of this performance report[6]

Financial Performance - The company's operating revenue for Q3 2024 was CNY 1,231,987,432.92, a decrease of 7.44% compared to the same period last year[1] - Net profit attributable to shareholders for Q3 2024 was CNY 325,631,579.67, an increase of 1.57% year-on-year[1] - The basic earnings per share for Q3 2024 was CNY 0.16, reflecting a year-on-year increase of 1.57%[1] - The net profit excluding non-recurring gains and losses for Q3 2024 was CNY 320,449,185.78, a slight increase of 0.04% year-on-year[1] - Total operating revenue for the first three quarters of 2024 reached CNY 4,073,361,821.56, a slight increase from CNY 4,022,002,501.05 in the same period of 2023, representing a growth of approximately 1.3%[12] - Net profit for the first three quarters of 2024 was CNY 1,427,390,948.39, compared to CNY 1,207,616,323.66 in 2023, reflecting an increase of approximately 18.2%[13] - The total comprehensive income for Q3 2024 reached CNY 1,446,486,664.53, compared to CNY 1,207,616,323.66 in Q3 2023, indicating an increase of about 19.8%[14] - The net profit attributable to shareholders of the parent company for Q3 2024 was CNY 1,051,719,466.85, an increase from CNY 887,400,407.26 in Q3 2023, representing a growth of approximately 18.5%[14] Cash Flow and Liquidity - The net cash flow from operating activities for Q3 2024 decreased by 91.39% to CNY 92,011,405.09 compared to the previous quarter[1] - The net cash flow from operating activities for the year-to-date period decreased by 44.52% to CNY 1,298,751,779.50 compared to the same period last year[4] - Cash flow from operating activities for the first three quarters of 2024 was CNY 1,298,751,779.50, down from CNY 2,341,139,295.54 in the same period of 2023, a decrease of about 44.5%[15] - The company reported a decrease in cash inflow from sales of goods and services, totaling CNY 4,018,855,673.47 for the first three quarters of 2024, down from CNY 4,974,086,029.35 in 2023, a decline of about 19.2%[15] - The company's cash and cash equivalents as of September 30, 2024, amount to approximately RMB 4.80 billion, an increase from RMB 4.55 billion at the end of 2023[9] - The cash and cash equivalents at the end of Q3 2024 amounted to CNY 3,540,499,295.77, compared to CNY 3,348,181,272.87 at the end of Q3 2023, showing an increase of about 5.7%[16] - The company experienced a net decrease in cash and cash equivalents of -1,407,031,634.47 RMB, contrasting with an increase of 1,399,409,326.02 RMB in the same period last year[24] Assets and Liabilities - Total assets as of the end of the reporting period were CNY 15,553,620,689.84, representing a year-on-year increase of 9.62%[2] - Total assets as of the end of Q3 2024 amounted to CNY 15,553,620,689.84, up from CNY 14,188,056,936.91 at the end of Q3 2023, representing an increase of approximately 9.6%[11] - Total liabilities increased to CNY 1,705,021,143.31 in Q3 2024 from CNY 1,433,686,959.69 in Q3 2023, indicating a growth of about 18.9%[11] - The company's total equity reached CNY 13,848,599,546.53 in Q3 2024, compared to CNY 12,754,369,977.22 in Q3 2023, reflecting an increase of approximately 8.6%[11] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 48,667, with the largest shareholder, China Biotechnology Co., Ltd., holding 902,500,488 shares, accounting for 45.64%[5] - There are no significant changes in the shareholding structure or major shareholder actions reported during the period[6] Research and Development - The company has ongoing research and development efforts, with development expenditures amounting to RMB 382.98 million, up from RMB 363.59 million[9] - Research and development expenses increased to CNY 98,702,282.76 in 2024 from CNY 58,350,420.20 in 2023, marking a rise of about 69.2%[13] Operational Challenges - The company’s operational cash flow remains negative, indicating ongoing challenges in generating positive cash flow from core business activities[23] - The company has not disclosed any new strategies or mergers and acquisitions in this reporting period[8] - The company has not adopted the new accounting standards for the current year, which may impact future financial reporting[25]

Financial Performance - Total operating revenue for the first three quarters of 2024 reached ¥407,336.18 million, an increase of 1.28% compared to ¥402,200.25 million in the same period last year[2] - Operating profit increased by 19.72% to ¥172,659.47 million from ¥144,224.99 million year-on-year[2] - Net profit attributable to shareholders of the listed company rose by 18.52% to ¥105,171.95 million, up from ¥88,740.04 million[2] - The basic earnings per share increased to ¥0.53, reflecting an 18.52% growth from ¥0.45[2] - The weighted average return on net assets improved to 10.27%, an increase of 0.67 percentage points from 9.60%[2] Assets and Equity - Total assets at the end of the reporting period were ¥1,555,362.07 million, a 9.62% increase from ¥1,418,805.69 million[2] - Shareholders' equity attributable to the listed company reached ¥1,064,125.90 million, up 8.33% from ¥982,257.92 million[2] - The number of shares outstanding increased by 20.00% to 197,737.14 million shares from 164,780.95 million shares[2] - The net asset per share attributable to shareholders decreased by 9.72% to ¥5.38 from ¥5.96[2] Revenue Drivers - The increase in sales revenue and profit margin was primarily driven by a rise in product sales prices year-on-year, contributing to an 18.52% increase in net profit attributable to shareholders[4]

Financial Performance - The company's operating revenue for the first half of 2024 reached ¥2,841,374,388.64, representing a 5.59% increase compared to ¥2,690,961,828.65 in the same period last year[13]. - The net profit attributable to shareholders of the listed company was ¥726,087,887.18, a 28.10% increase from ¥566,799,608.15 in the previous year[13]. - The net profit after deducting non-recurring gains and losses was ¥723,176,364.88, reflecting a 29.35% increase from ¥559,081,561.15 in the same period last year[13]. - The net cash flow from operating activities was ¥1,206,740,374.41, showing a decrease of 5.12% compared to ¥1,271,885,437.82 in the previous year[13]. - The total assets at the end of the reporting period were ¥15,139,377,670.87, which is a 6.71% increase from ¥14,188,056,936.91 at the end of the previous year[13]. - The net assets attributable to shareholders of the listed company increased by 5.02% to ¥10,315,627,409.75 from ¥9,822,579,168.54 at the end of the previous year[13]. - Basic earnings per share for the first half of 2024 were ¥0.37, up 28.10% from ¥0.29 in the same period last year[14]. - The diluted earnings per share also stood at ¥0.37, reflecting the same percentage increase of 28.10% compared to the previous year[14]. - The weighted average return on net assets increased by 0.92 percentage points to 7.16% from 6.24% in the previous year[14]. Market and Industry Overview - The company operates in the blood products industry, focusing on the research, production, and sales of blood products, which are essential for medical emergencies and public health[17]. - The main products include human albumin, immunoglobulins, and coagulation factors, which are critical for treating various medical conditions[17]. - The market for blood products in China is expected to continue expanding due to the aging population and increasing healthcare demands[17]. - The company has identified a substantial growth opportunity in the domestic market, with current production and per capita consumption still below levels seen in developed countries[17]. Research and Development - The company maintains a leading position in R&D capabilities, with over 100 researchers and advanced R&D facilities[20]. - The company focuses on product price increases and cost control as key drivers for revenue and profit growth[20]. - The company has over ten new products in development, including blood products and gene recombinant products[20]. - The company has established a comprehensive quality management system for R&D, ensuring high standards throughout the product lifecycle[19]. Operational Highlights - The company operates 102 plasma collection stations across 16 provinces/regions, with 80 stations currently in operation[20]. - The company collected 1,294 tons of plasma, accounting for approximately 20% of the total plasma collection in the domestic industry[20]. - New production bases in Chengdu, Kunming, and Lanzhou are designed to have a production capacity of 1,200 tons each, enhancing operational quality and efficiency[20]. - The average product yield of the company's blood products remains at an industry-leading level, with continuous improvements in production efficiency and quality management[32]. Financial Management and Investments - The company reported a significant increase in employee compensation liabilities, rising by 878.88% to approximately ¥233.60 million, reflecting accrued but unpaid year-end bonuses[44]. - The company completed multiple capital increases for plasma stations to support internal development and address funding needs[46]. - The cash flow from investment activities showed a significant improvement, with a net outflow of approximately -¥31.85 million compared to -¥646.69 million in the previous year[40]. - The company has made significant equity investments totaling RMB 83,500,000, with 100% ownership in multiple plasma collection companies[47]. Environmental Responsibility - The company has implemented strict compliance with national environmental protection laws and standards for waste treatment[66]. - The company’s subsidiaries have consistently maintained emissions below the regulatory limits for both wastewater and air pollutants[67]. - The company is committed to environmental responsibility and has taken measures to ensure compliance with pollution discharge standards[68]. - The company has established an energy certification system (ISO 50001) to strengthen energy conservation and emission reduction efforts[85]. Governance and Compliance - The company is focused on enhancing its governance structure, ensuring that all shareholder meetings and resolutions are legally valid and effective[63]. - The company has established a special incentive program for research personnel to encourage innovation and accelerate research progress[65]. - The company has implemented a comprehensive internal control system to enhance compliance and risk management, ensuring legal and regulatory adherence[37]. - The company has not reported any exceedance in solid waste emissions across its subsidiaries[68]. Related Party Transactions - The company commits to minimizing related party transactions and ensuring they are conducted on fair and reasonable commercial terms[94]. - The company ensures that related party transactions do not illegally transfer funds or profits from Tian Tan Biological to protect the interests of minority shareholders[94]. - The expected related party transaction amount for 2024 is estimated at 2,104.03 million RMB for purchase and sale of goods and provision of services, and 33.06 million RMB for leasing[96]. Shareholder Information - The total number of common stock shareholders was 44,169[108]. - The company completed a capital increase of 329,561,908 shares, raising the total share capital from 1,647,809,538 shares to 1,977,371,446 shares[108]. - The total number of shares held by the top ten unrestricted shareholders did not change compared to the previous period[110]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[112]. Financial Reporting and Accounting Policies - The financial reports comply with the requirements of the enterprise accounting standards, reflecting the company's financial position and operating results accurately[148]. - The company recognizes significant capitalized R&D projects if their amount exceeds 0.5% of total assets[152]. - The company’s accounting year runs from January 1 to December 31[149]. - The company measures financial assets at fair value, with gains or losses recognized in the current profit or loss, unless part of a hedging relationship[160].